UPDATE: Goldman Sachs Downgrades Seres Therapeutics (MCRB) to Sell

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to UPDATE: Goldman Sachs Downgrades Seres Therapeutics (MCRB) to Sell

Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis

July 22, 2021 7:33 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative... More

Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis

July 22, 2021 7:00 AM EDT

Primary endpoint of clinical remission compared to placebo was not achieved

Both dosing regimens of SER-287 were generally well tolerated

Open label and maintenance portions of the SER-287 study will be closed

Microbiome endpoints and analyses expected in the second half of 2021

Company to host a conference call at 8:30 a.m. ET

CAMBRIDGE, Mass.--(BUSINESS... More